(Q37964276)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

New options and perspectives for proteinuria management after kidney transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

main subject

kidney transplantation

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

María José Soler

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alex Gutierrez

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Julio Pascual

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

published in

Transplantation Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

44-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22137732%20AND%20SRC:MED&resulttype=core&format=json

Proteinuria after kidney transplantation, relationship to allograft histology and survival

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Mechanisms and management of proteinuria in kidney transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Proteinuria as a therapeutic target in patients with chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Significance and management of proteinuria in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Aliskiren combined with losartan in type 2 diabetes and nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Human recombinant ACE2 reduces the progression of diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

ACE2 and diabetes: ACE of ACEs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Renoprotective role of the vitamin D receptor in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

1,25-Dihydroxyvitamin D3decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Role of endothelin-1 in clinical hypertension: 20 years on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Endothelin, hypercholesterolemia and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Pathophysiology of endothelin in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

7 January 2021

Endothelin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Protective effects of endothelin antagonists in chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Avosentan for overt diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Glomerular endothelial glycocalyx constitutes a barrier to protein permeability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

The role of sulodexide in the treatment of diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Effect of pentoxifylline on graft function of renal transplant recipients complicated with chronic allograft nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

The extended protein kinase C superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Protein kinase C isozymes and the regulation of diverse cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Protein kinase C activation and its pharmacological inhibition in vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

The effect of ruboxistaurin on nephropathy in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

New pharmacological treatments for improving renal outcomes in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Hepatocyte growth factor and the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Preservations of nephrin and synaptopodin by recombinant hepatocyte growth factor in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Renal Bone Morphogenetic Protein-7 Protects against Diabetic Nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006

Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.07.006